Ocular Therapeutix公司 OCUL 深 滬
已收盤 08-07 16:00:00 美东时间
9.19
+0.450
+5.15%
華盛通- 最 高9.20
- 今 開8.80
- 成交量 201.66万股
- 最 低 8.80
- 昨 收 8.74
- 總市值 20.18亿
- 52周最高 16.44
- 市盈率 靜 --
- 換手率 0.92%
- 52周最低 6.2301
- 委 比 1.85%
- 總股本 2.20亿
- 歷史最高 44.19
- 量 比 0.92
- 振 幅 4.58%
- 歷史最低 1.995
- 每 手 1
- 風險率 1.78%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多财报速睇 | Ocular Therapeutix公司 2026财年Q2营收0.13亿美元，同比增长0.1%；归母净利润亏损0.79亿美元，同比亏损扩大16.1%
华盛资讯8月4日讯，Ocular Therapeutix公司公布2026财年Q2业绩，公司Q2营收0.13亿美元，同比增长0.1%，归母净利润亏损0.79亿美元，同比亏损扩大16.1%。
08-04 01:40
Ocular Therapeutix Q2 EPS $(0.35) Beats $(0.40) Estimate, Sales $13.475M Beat $13.199M Estimate
Ocular Therapeutix (NASDAQ:OCUL) reported quarterly losses of $(0.35) per share which beat the analyst consensus estimate of $(0.40) by 10.26 percent. This is a 10.26 percent increase over losses of $(0.39) per share from the same period last year. The company reported quarterly sales of $13.475 mil...
08-03 19:06
OCUL’s OTX-TKI Extension Study: Long-Term Safety Data Could Shape Wet AMD Market
Ocular Therapeutix Inc ($OCUL) announced an update on their ongoing clinical st...
07-02 00:31
美股大行评级 | 潜在涨幅135.66%！Ocular Therapeutix获Chardan Capital升目标价至23美元，维持"买入"评级
今日重点评级关注：Chardan Capital：维持Ocular Therapeutix"买入"评级，目标价从21美元升至23美元；Guggenheim：维持Amylyx Pharmaceuticals"买入"评级，目标价从30美元升至40美元
06-26 17:42
Chardan Capital Maintains Buy on Ocular Therapeutix, Raises Price Target to $23
Chardan Capital analyst Andreas Argyrides maintains Ocular Therapeutix (NASDAQ:OCUL) with a Buy and raises the price target from $21 to $23.
06-25 21:34
Ocular Therapeutix Plans Q4 2026 NDA Submission For AXPAXLI In Wet AMD Based On SOL-1 Data, Removes SOL-R Efficacy From Filing And Extends Trial Timeline To 2028
Per May 2026 Type C meeting, AXPAXLI NDA for wet AMD to be based on SOL-1 Week 52 efficacy and safety plus interim SOL-R safety data Ocular to conduct interim SOL-R safety analysis in 4Q 2026 to reach >300 patients of safety data across SOL-1 and SOL-R, in alignment with FDA requirements Complete AX...
06-17 20:46
美股大行评级 | 潜在涨幅20%！15家机构集体上调AMD目标价；Lumentum、神经分泌生物科学、伊顿公司、美国电力等获多家大行上调目标价
今日重点评级关注：Citizens：维持Avalo Therapeutics"跑赢大市"评级，目标价从52美元升至62美元；BTIG：维持Avalo Therapeutics"买入"评级，目标价从40美元升至58美元
05-07 12:37
RBC Capital Reiterates Outperform on Ocular Therapeutix, Maintains $30 Price Target
RBC Capital analyst Lisa Walter reiterates Ocular Therapeutix (NASDAQ:OCUL) with a Outperform and maintains $30 price target.
05-06 23:49
